All In Biotech

Drug Trial Radar · NCT03329508

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.

Last checked: Nov 20, 2026Latest source record: Mar 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 544 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

544

Actual

Start

Jan 19, 2018

Primary completion

Aug 23, 2021

Study completion Oct 31, 2021

Sponsor

Lead sponsor
Pharma Two B Ltd.Industry
Sponsor type
Industry
First posted
Nov 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

P2B001 is an investigational drug that comprised of low doses of two drugs, pramipexole and rasagiline, which are both approved drugs and routinely used in standard therapy for Parkinson's disease. The two drugs work in two different mechanisms that help each other, so there is a reason to believe that their combined activity will be better than each individual drug, and that lower doses can be used without losing the therapeutic effect. Thus, the development of P2B001 is intended to provide a combination of low doses of these two drugs, in an improved formulation, that is hoped to be more effective in controlling Parkinson's disease symptoms and with less side effects than each of the drugs taken alone or the current available commercial drugs taken together. In a previously completed clinical trial a significant improvement in Parkinson's disease symptoms was seen in patients treated with P2B001 compared to patients that were treated with placebo. In this phase 3 study , the safety and efficacy of P2B001 will be assessed by comparing P2B001 to its individual components pramipexole and rasagiline. This will be done by monitoring the motor and non-motor symptoms, evaluating responses participants provide on questionnaires relating to Parkinson's disease and quality of life that will be completed on every visit. In addition, this study will also compare P2B001 to a marketed drug of pramipexole ER. Approximately 525 patients will participate in this research study and the participation in this study will last between 14 to 18 weeks.

Conditions

  • Parkinson Disease
  • Early Parkinson's Disease

Interventions

  • P2B001 0.6/0.75 mgDrug

    Fixed low dose extended release combination capsule of pramipexole and rasagiline

  • Rasagiline 0.75 mgDrug

    Rasagiline 0.75 mg oral extended release capsule, component

  • Pramipexole 0.6 mgDrug

    Pramipexole 0.6 mg oral extended release capsule, component

  • Marketed Pramipexole ERDrug

    Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160).Time frame: baseline to week 12

Locations

72 sites in 4 countries. Site status is shown where the registry gives one.

  • P2B001/003 Site Scottsdale

    Scottsdale, Arizona

  • P2B001/003 study site Scottsdale

    Scottsdale, Arizona

  • P2B001/003 Study site little Rock

    Little Rock, Arkansas

  • P2B001 site Los Angeles

    Los Angeles, California

  • P2B001 Study site Englewood,

    Englewood, Colorado

  • P2B001 Study Vernon

    Vernon, Connecticut

  • P2B001/003 site Boca Raton

    Boca Raton, Florida

  • P2B001/003 Site Boca Raton

    Boca Raton, Florida

  • P2B001/003 study site Jacksonville

    Jacksonville, Florida

  • P2B001/003 site Miami

    Miami, Florida

  • P2B001/003 Site Port Charlotte

    Port Charlotte, Florida

  • P2B001/003 Site Sarasota

    Sarasota, Florida

  • P2B001/003 Site Tampa

    Tampa, Florida

  • P2B001/003 Site Augusta

    Augusta, Georgia

  • P2B001/003 study site Honolulu

    Honolulu, Hawaii

  • P2B001/003 site Chicago

    Chicago, Illinois

  • P2B001/003 Site Winfield

    Winfield, Illinois

  • P2B001/003 site Kansas City

    Kansas City, Kansas

  • P2B001/003 Site Lexington

    Lexington, Kentucky

  • P2B001/003 study site Boston

    Boston, Massachusetts

  • P2B001/003 Site East Lansing

    East Lansing, Michigan

  • P2B001/003 study site west Bloomfield

    West Bloomfield, Michigan

  • P2B001/003 Site Golden Valley

    Golden Valley, Minnesota

  • P2B001/003 site St. Louis

    St Louis, Missouri

  • P2B001/003 study site New Hampshire

    Lebanon, New Hampshire

  • P2B001/003 Study site Camden

    Camden, New Jersey

  • P2B001 Study site Edison

    Edison, New Jersey

  • P2B001/003 Study site Albuquerque

    Albuquerque, New Mexico

  • P2B001/003 Study site Brooklyn

    Brooklyn, New York

  • P2B001/003 Site Commack

    Commack, New York

  • P2B001/003 New York

    New York, New York

  • P2B001 Study site Syracuse

    Syracuse, New York

  • P2B001/003 Study site Williamsville

    Williamsville, New York

  • P2B001/003 Site Asheville

    Asheville, North Carolina

  • P2B001 study site Cincinnati

    Cincinnati, Ohio

  • P2B001/003 Site Toledo

    Toledo, Ohio

  • P2B001/003 Study site Hershey

    Hershey, Pennsylvania

  • P2B001/003 Greenville

    Greenville, South Carolina

  • P2B0011/003 Study Veracity Neuroscience

    Memphis, Tennessee

  • p2B001/003 Study site Memphis

    Memphis, Tennessee

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.